Psychiatric complications of L-dopa: Physiopathology and treatment;Complicaciones psiquiatricas de la L-dopa: Fisiopatologia y tratamiento

Revista de Neurologia

Volumn 25, Issue SUPPL. 2, 1997, Pages

  Castro Garcia A ^a  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

Author keywords

L dopa; Parkinson's disease; Psychiatric complications

Indexed keywords

ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; LEVODOPA; NEUROLEPTIC AGENT; ANTIPARKINSON AGENT;

AFFECTIVE NEUROSIS; ANXIETY NEUROSIS; DOPAMINERGIC SYSTEM; ELECTRIC SHOCK; HUMAN; MENTAL DISEASE; PARKINSON DISEASE; PATHOPHYSIOLOGY; PSYCHOSIS; REVIEW; CHEMICALLY INDUCED DISORDER; DOSE RESPONSE; DRUG ADMINISTRATION; ELECTROCONVULSIVE THERAPY; INCIDENCE; PSYCHOLOGICAL ASPECT;

ANTIDEPRESSIVE AGENTS; ANTIPARKINSON AGENTS; ANTIPSYCHOTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ELECTROCONVULSIVE THERAPY; HUMANS; INCIDENCE; LEVODOPA; MENTAL DISORDERS; PARKINSON DISEASE;

EID: 0030869639     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (11)

1. Gumming JL. Intelectual impairment in Parkinson's disease: clinical, patological and biochemical correlates. J Geriatr Psychiatry Neurol 1988; 1:24-36.
2. Koller WC, Handbook of Parkinson's disease. New York: Marcel Dekker Inc.; 1987. p. 132.
3. Saint-Cyr JA, Taylor AE, Lang AE. Neuropsycological and psychiatric side effects in the treatment of Parkinson's disease. Neurology 1993; 43 (Suppl): 47-52.
4. Goodwin FK. Psychiatric side effects of levodopa in man. JAMA 1971 ; 218: 1915-20.
5. Celesia GG, Barr AN. Psychosis and other psychiatric manifestations of levodopa therapy. Arch Neurol 1970; 23: 193-200,
6. Jenkins RB, Groh RH. Mental symptoms in parkinsonian patients treated with L-dopa. Lancet 1970; 2: 177-80.
7. Keenan RE. The Eaton collaborative study of levodopa, therapy in parkinsonism: a summary. Neurology 1970; 20: 46-59.
8. Langrall HM. The Roche collaborative study of levodopa, realbefore the second Roche Symposium on levodopa. Nutley NJ, 1970.
9. Goetz CG, Tanner CM, Klawans HL. Pharmacology of hallucinations individual by long-term drug therapy. Am J Psychiatry 1982; 139: 494-7.
10. Pederzoli M, Girotti F, Scigliano G, et al. L-dopa long-term treatment in Parkinson's disease: age-related side effects. Neurology 1983; 33: 1518-22.
11. Stein MB, Heuser IJ, Vade TW. Anxiety disorders in patients with Parkinson's disease. Am J Psychiatry 1990; 147; 217-20.